Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.68 |
| ▸ | HTR2A | P28223 | 16/20 | 0.68 |
| ▸ | DRD2 | P14416 | 13/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398868 | 0.94 | HTR1A (0.67) | HTR1AKCNH2HTR2ADRD2DRD3 | |
| SCHEMBL6402177 | 0.87 | HTR1A (0.57) | HTR1AKCNH2HTR2ADRD2 | |
| SCHEMBL6400115 | 0.87 | HTR1A (0.68) | HTR1AKCNH2HTR2ADRD2DRD3 | |
| SCHEMBL6397693 | 0.86 | HTR1A (0.56) | HTR1AKCNH2HTR2ADRD2 | |
| SCHEMBL5738315 | 0.85 | HTR1A (0.72) | HTR1AKCNH2HTR2ADRD2DRD3 | |
| SCHEMBL5400725 | 0.85 | HTR1A (0.72) | HTR1AKCNH2HTR2ADRD2DRD3 | |
| SCHEMBL5400723 | 0.85 | HTR1A (0.72) | HTR1AKCNH2HTR2ADRD2DRD3 | |
| SCHEMBL6399742 | 0.83 | HTR1A (0.57) | HTR1AKCNH2HTR2ADRD2 | |
| SCHEMBL6400159 | 0.82 | HTR1A (0.75) | HTR1AKCNH2HTR2ADRD2DRD3 | |
| SCHEMBL6400755 | 0.82 | HTR1A (0.55) | HTR1AKCNH2HTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | claimed |
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
| US-20050037919-A1 | Metallocenes and catalyst compositions derived therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | HTR1A 61/4885KCNH2 114/4885HTR2A 195/4885 |
| US-20050037919-A1 | Metallocenes and catalyst compositions derived therefrom | HMOX1, RTF1, OPRM1 | HTR1A 698/4885KCNH2 4123/4885HTR2A 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.